Solid Biosciences Inc. (SLDB) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
141 Portland Street
Cambridge, MA 02139
United States of America (the)
Phone
617 337 4680
Website
Sector
Healthcare
Industry
Biotechnology
Employees
100
First IPO Date
January 26, 2018
| Name | Title | Pay | Year Born |
| Ilan Ganot | Co-founder, Strategic Advisor to the Chief Executive Officer & Director | 40,000 | 1974 |
| Alexander G. Cumbo | President, Chief Executive Officer & Director | 1.11M | 1971 |
| Ian F. Smith | Executive Chair | 75,000 | 1966 |
| Kevin Tan | Chief Financial Officer & Treasurer | 607,181 | 1978 |
| Gabriel Brooks | Chief Medical Officer | 772,732 | 1977 |
| David Tyronne Howton Jr. | Chief Operating Officer & Secretary | 791,718 | 1972 |
| Annie Ganot | Co-Founder & Vice President of Patient Advocacy | 0 | N/A |
| Nicole Anderson | Senior Director of Investor Relations & Corporate Communications | 0 | N/A |
| Paul Herzich | Chief Technology Officer | 0 | 1978 |
| Jessie Hanrahan | Chief Regulatory & Preclinical Operations Officer | 0 | 1976 |
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.